HeartFlow is a medical technology company transforming the way cardiovascular disease is diagnosed and treated. With our HeartFlow Analysis, a non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease--the number one killer of men and women worldwide.
HeartFlow is backed by decades of scientific research and development and leverages the latest advancements in technology to help set a new standard of care for diagnosing cardiovascular care worldwide. Cleared for use in the United States, Canada, Europe and Japan with offices in Mountain View, Austin, London and Japan, HeartFlow's footprint is growing rapidly. HeartFlow has received more than $215 million dollars in funding in a recent Series F financing round, is pre-IPO and leverages the latest technology including deep learning and computational fluid dynamics.
Vastuuvapauslauseke: WebCatalog ei ole sidoksissa, yhteydessä, valtuutettu, hyväksytty eikä millään tavoin virallisesti liitetty HeartFlow kanssa. Kaikki tuotenimet, logot ja brändit ovat omistajiensa omaisuutta.
